Melissa Orilall was named Principal Financial Officer of MiNK Therapeutics, Inc., effective March 13, 2026. As of November 14, 2026, MiNK Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 2, 2026 to March 19, 2026, naming 1 appointment and 1 departure (Form 8-K, March 19, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like MiNK Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
MiNK Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-02 to 2026-03-19. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as MiNK Therapeutics, Inc. files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-19 | In | Principal Financial Officer | 2026-03-13 | 8-K, 2026-03-19 | |
| 2026-01-02 | Out | 2025-12-29 | 8-K, 2026-01-02 |
Selling to them or working with them? See who runs MiNK Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Watch MiNK Therapeutics, Inc.
Get an email when MiNK Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on MiNK Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on MiNK Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on MiNK Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Why did they leave? What the filings say
For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.
- Robert Kadlec (filed 2026-01-02):
Dr. Kadlec joined the Company's Board in October 2024 and contributed valuable perspective informed by his extensive experience in medicine, public health preparedness, and national service.
Who leads MiNK Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Principal Financial Officer: Melissa Orilall, appointed, effective 2026-03-13 (filed 2026-03-19).
New leaders reset buying decisions — get the Full Report on MiNK Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Principal Financial Officer at MiNK Therapeutics, Inc., with the record behind each one.
Find candidates like Principal Financial Officer at MiNK Therapeutics, Inc.Every change, in the filing's words
Appointed: Melissa Orilall, Principal Financial Officer, effective 2026-03-13
Effective March 13, 2026, MiNK Therapeutics Inc.'s (the "Company") Board of Directors appointed Melissa Orilall, Agenus Inc.'s ("Agenus") current Vice President, Global Financial Operations to serve as the Company's Principal Financial Officer.
- Ms. Orilall, provides services to the Company through an Amended and Restated Intercompany Services Agreement between the Company and Agenus.
- Ms. Orilall, age 37, joined Agenus in November 2017 and has served as Vice President, Global Financial Operations at Agenus and through the Amended and Restated Intercompany Services Agreement, MiNK, since March 2026 where she is responsible for overseeing general accounting, month-end and quarterly close procedures and financial planning and analysis.
- Prior to November 2017, Ms. Orilall worked at Whitehead Institute for Biomedical Research where she focused on financial planning and modeling.
- Her experience also includes several years in corporate banking with portfolio management and operational responsibilities.
- Ms. Orilall holds a Canadian CPA designation and an Honors BAS in Accounting from York University in Toronto.
- There were no new arrangements or modifications to existing arrangements entered into with Ms. Orilall in connection with her designation as the Company's Principal Financial Officer.
- Ms. Orilall does not receive any compensation directly from the Company for her services to the Company.
Departing: Robert Kadlec, effective 2025-12-29
On December 29, 2025, Robert Kadlec, MD, resigned from the Board of Directors of MiNK Therapeutics, Inc. (the "Company"), including all committees thereof, effective December 29, 2025, in connection with his acceptance of a senior public service role within the United States government as Assistant Secretary of War for Nuclear Deterrence and Chemical and Biological Defense Policy and Programs.
- His resignation is associated with his acceptance of a senior public service role of significant responsibility and distinction, consistent with his long-standing commitment to service.
- The Company congratulates Dr. Kadlec on this appointment and expresses its sincere appreciation for his engagement, perspective, and counsel during his time on the Board.
Tools for this story
Each opens in a new tab, filled in for MiNK Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
